2026 China Vaccine Industry Segmentation: Pneumonia Vaccine Market Analysis; Wholesale signing volume has declined【Gallery】

MaticHoleFiller · 2026-03-28T11:53:51+00:00

The Chinese pneumonia vaccine market is gradually approaching saturation, with the number of approvals expected to decrease to 109 by 2025. Among them, the 13-valent vaccine accounts for 75%, with Yuxi Walvax being the main manufacturer, issuing as many as 46 approvals.

MaticHoleFiller

2026-03-28 11:53:51

Abstract generation in progress

Translated from: Qianzhan Industry Research Institute

The following data and analysis are from the “Analysis Report on the Development Prospects and Investment Strategic Planning of China’s Vaccine Industry” published by the Human Vaccine Research Group of Qianzhan Industry Research Institute.

Major listed companies in the industry: Hualan Biological (002007), Zhifei Biological (300122), Kangtai Biological (300601), Watson Bio (300142), CanSino (688185), Changchun High-tech (000661), Fosun Pharma (600196), Gendi Ke (688670), Olin Bio (688319), Baike Bio (688276), etc.

Core data of this article: Number of batches issued for pneumonia vaccines, number of batches issued by pneumonia vaccine manufacturers, etc.

Pneumonia vaccines are mainly divided into 23-valent and 13-valent types.

China’s pneumonia vaccines mainly include two types: the 23-valent pneumococcal polysaccharide vaccine and the 13-valent pneumococcal conjugate vaccine. The 13-valent pneumococcal conjugate vaccine is used for prevention in infants from 6 weeks to 15 months old, currently produced by Pfizer; the 23-valent pneumococcal polysaccharide vaccine mainly targets children over 2 years old and high-risk groups, with vaccination recommended for individuals aged 60 and above. Current manufacturers include Chengdu Institute, Merck, and Watson Bio.

The number of batches issued for pneumonia vaccines is gradually decreasing.

From 2021 to 2025, the total number of batches issued for pneumonia vaccines in China is overall decreasing. According to data disclosed by the China National Institute for Food and Drug Control, the number of batches issued for pneumonia vaccines in China in 2025 will be 109, a decrease of 2 batches compared to 2024.

In 2025, the pneumonia vaccine with the highest number of issued batches in China is the 13-valent pneumococcal polysaccharide conjugate vaccine, with a total of 82 batches issued, accounting for 75% of the total number of issued batches; the 23-valent pneumococcal polysaccharide vaccine accounts for 25%, with a total of 27 batches issued.

Yuxi Watson has the highest number of issued batches for pneumonia vaccines in 2025.

Yuxi Watson is a major participant in China’s pneumonia vaccine industry. In 2025, the number of batches issued for the company’s pneumonia vaccines is 46, accounting for 42% of the total; Pfizer ranks second, with a number of issued batches of 23, accounting for 21% of the total.

Yuxi Watson has a high number of batches issued for the 13-valent vaccine.

In 2025, the number of batches issued for Yuxi Watson’s 13-valent pneumococcal polysaccharide conjugate vaccine is 39, accounting for 48% of the overall quantity; the number of batches issued for Chengdu Institute’s 23-valent pneumococcal polysaccharide vaccine is 10, accounting for 37% of the overall quantity of segmented products.

For more in-depth industry research and analysis, see the “Analysis Report on the Development Prospects and Investment Strategic Planning of China’s Vaccine Industry” from Qianzhan Industry Research Institute.

At the same time, Qianzhan Industry Research Institute also provides solutions such as industrial big data, industry research reports, industrial planning, park planning, industrial investment promotion, industrial maps, smart investment promotion systems, industry position certification, IPO consulting/research on fundraising investment, and IPO working manuscript consulting. Quoting content from this article in any public information disclosure such as prospectuses or company annual reports requires formal authorization from Qianzhan Industry Research Institute.

More in-depth industry analysis can be found in the [Qianzhan Economist APP], where you can also interact with 500+ economists/senior industry researchers.

A wealth of information and precise interpretations can be found in the Sina Finance APP.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes